CRP and obesity due to melanocortin 4 receptor deficiency: Similar to the findings of our study, previous authors have demonstrated excellent health outcomes for individuals with obesity or MetS undergoing RYGB including a remission of comorbidities, reduction in systemic inflammation, and significant reduction in high CRP levels [48,49].